Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (351-360 of 440) with videos related to

Pageof 44
Sort By:
British Journal of Cancer|July 25, 2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinomaR Donald Harvey, Bradley C Carthon, Colleen Lewis, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood Cancer Journal|April 15, 2020
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agentsRoberto Mina, Nisha S Joseph, Francesca Gay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.
Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.
Cancer|August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trialAjay K Nooka, Adam D Cohen, Hans C Lee, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
Pageof 44

Showing results (351-360 of 440) with videos related to

Sort By:
Pageof 44
British Journal of Cancer|July 25, 2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinomaR Donald Harvey, Bradley C Carthon, Colleen Lewis, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood Cancer Journal|April 15, 2020
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agentsRoberto Mina, Nisha S Joseph, Francesca Gay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.
Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.
Cancer|August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trialAjay K Nooka, Adam D Cohen, Hans C Lee, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
Pageof 44